Abstract
Perspective
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainReferences
- Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.Cephalalgia. 1988; 8: 1-96
- The International Classification of Headache Disorders: 2nd edition.Cephalalgia. 2004; 24: 9-160
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial.Cephalalgia. 2010; 30: 793-803
- OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program.Headache. 2011; 51: 1358-1373
- The HIT-6™: A User's Guide.QualityMetric Incorporated, Lincoln, RI2002
- Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study (The Australian KEPPRA Headache Trial [AUS-KHT]).Cephalalgia. 2011; 31: 530-536
- Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment.Neurology. 2008; 71: 559-566
- Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.Headache. 2010; 50: 1406-1418
- Topiramate for migraine prevention: A randomized controlled trial.JAMA. 2004; 291: 965-973
- A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.Headache. 2011; 51: 21-32
- Designing pain research from the patient's perspective: What trial end points are important to patients with chronic pain?.Pain Med. 2001; 2: 309-316
- Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test.J Clin Epidemiol. 2006; 59: 374-380
- Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1.Cephalalgia. 2009; 29: 1180-1187
- The number needed to treat: A clinically useful measure of treatment effect.BMJ. 1995; 310: 452-454
- Amitriptyline in the prophylactic treatment of migraine and chronic daily headache.Headache. 2010; 51: 33-51
- Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.Cephalalgia. 2007; 27: 814-823
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.Cephalalgia. 2010; 30: 804-814
- The impact of topiramate on health-related quality of life indicators in chronic migraine.Headache. 2007; 47: 1398-1408
- OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.Headache. 2010; 50: 921-936
- FDA's Temple discusses how to measure drug efficacy when mean effect is limited.The Pink Sheet. 2010;
- Impact of headache on quality of life in a general population survey in France (GRIM2000 Study).Headache. 2004; 44: 571-580
- Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.Pain. 2009; 146: 238-244
- Validating use of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) across migraine disorders.Value Health. 2010; 13 ([ISPOR abstract PND26]): A142
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 24(Suppl 1):9-160, 2004
- A six-item short-form survey for measuring headache impact: The HIT-6.Qual Life Res. 2003; 12: 963-974
- An assessment of clinically useful measures of the consequences of treatment.N Engl J Med. 1988; 318: 1728-1733
- Anxiety and depression are associated with migraine and pain in general: An investigation of the interrelationships.J Pain. 2013; 14: 363-370
- Migraine, quality of life, and depression: A population-based case-control study.Neurology. 2000; 55: 629-635
- OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.Neurology. 2011; 77: 1465-1472
- Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1).Headache. 2000; 40: 204-215
- A double-blind comparison of onabotulinumtoxinA (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: A pilot study.Headache. 2009; 49: 1466-1478
- Quality-of-life differences between patients with episodic and transformed migraine.Headache. 2001; 41: 573-578
- Safety of botulinum toxin type A: A systematic review and meta-analysis.Curr Med Res Opin. 2004; 20: 981-990
- The International Classification of Headache Disorders, 3rd edition (beta version).Cephalalgia. 2013; 33: 629-808
- Measuring the functional status and well-being of patients with migraine headache.Headache. 1994; 34: 337-343
- Self-reported comorbid pains in severe headaches or migraines in a US national sample.Headache. 2012; 52: 946-956
- The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.Qual Life Res. 2013; 22: 1123-1133
- Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine.Health Qual Life Outcomes. 2014; 12: 117
- Chronic daily headache prophylaxis with tizanidine: A double-blind, placebo-controlled, multicenter outcome study.Headache. 2002; 42: 470-482
- Double-blind trial of fluoxetine: Chronic daily headache and migraine.Headache. 1994; 34: 497-502
- Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures.Headache. 2009; 49: 1153-1162
- Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults.Cephalalgia. 2008; 28: 484-495
- Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial.Headache. 2007; 47: 170-180
- Classification of daily and near-daily headaches: Field trial of revised IHS criteria.Neurology. 1996; 47: 871-875
- Headache prophylaxis with BoNTA: Patient characteristics.Headache. 2010; 50: 63-70
- Topiramate in migraine prevention: Results of a large controlled trial.Arch Neurol. 2004; 61: 490-495
- Topiramate in the treatment of chronic migraine.Cephalalgia. 2003; 23: 820-824
- Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controlled study.Neurology. 2003; 61: 1753-1759
- Guidelines for controlled trials of drugs in migraine: Second edition.Cephalalgia. 2000; 20: 765-786
- Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: Results of the German Headache Consortium study.Pain. 2013; 154: 484-492
- The effect of sodium valproate on chronic daily headache and its subgroups.J Headache Pain. 2008; 9: 37-41
Article info
Publication history
Footnotes
Funded by Allergan, Inc.
D.W.D., within the past 12 months, has served on advisory boards and has consulted for Allergan, Amgen, Alder, Arteaus, Pfizer, Merck, ENeura, NuPathe, Eli Lilly & Company, Autonomic Technologies, WL Gore, Ethicon J&J, Zogenix, Supernus, Labrys, and Bristol-Myers Squibb. D.W.D. has received funding for travel, speaking, or editorial activities from the following: CogniMed, Scientiae, IntraMed, SAGE Publishing, Sun Pharma, Allergan, Lippincott Williams & Wilkins, Oxford University Press, Cambridge University Press, Miller Medical, and Annenberg for Health Sciences; he serves as Editor-in-Chief and on the editorial boards of The Neurologist, Lancet Neurology, and Postgraduate Medicine and has served as Editor-in-Chief of Headache Currents and as an Associate Editor of Headache. He receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010). C.C.T. is an employee of, holds stock/stock options in, and holds a patent with Allergan, Inc.
R.E.D. is an employee of and holds stock/stock options in Allergan, Inc.
H.C.D. received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Addex Pharma, Allergan, Almirall, Autonomic Technology, AstraZeneca, Bayer Vital, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Coherex, CoLucid, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Lilly, La Roche, 3M Medica, Medtronic, Menerini, Minster, MSD, Neuroscore, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi, St. Jude, and Weber & Weber. He has received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GSK, Janssen-Cilag, MSD, and Pfizer. Headache research at the Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), and the European Union. H.C.D. has no ownership interest and does not own stocks of any pharmaceutical company.
R.B.L. receives research support from the NIH [PO1 AG03949 (Program Director), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Mentor), and K23NS47256 (Mentor), the National Headache Foundation, and the Migraine Research Fund; serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache; has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics (a company without commercial products); and serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, Endo, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Pfizer, and Vedanta.
S.K.A. has received research support from Advanced Bionics, Allergan, Inc, Boston Scientific, eNeura, GlaxoSmithKline, MAP Pharmaceuticals, Inc, Merck, NuPathe, Inc, and the NIH; has served as a consultant for Allergan, Arteaus Therapeutics, Merck, and eNeura; and has received honoraria from Merck, GlaxoSmithKline, Allergan, Inc, Nautilus, and Zogenix, Inc.
M.E.N. was an employee of Imprint Publication Science at the time of this research. Her work was funded by Allergan.
S.D.S. is on the advisory panel of and receives honoraria from Allergan, Amgen, Capnia, Coherex, GlaxoSmithKline, Iroko Pharmaceuticals, Lilly, MAP, Medtronic, Merck, Neuralieve, NINDS, NuPathe, Pfizer, and St. Jude Medical. He serves as a consultant for and receives honoraria from Amgen, MAP, Nautilus, Novartis, Opti-Nose, and Zogenix. Dr. Silberstein's employer receives research support from Allergan, BMS, Cumberland, ElectroCore, Lilly, Merck, Opti-Nose, St. Jude Medical, and Troy Healthcare.
